Title: Effect of Fluvoxamine on Interluekin-6 level of COVID-19 patients, hospitalized in ICU: A randomized clinical trial
In reviewing the laboratory studies, we observe the use of some drugs with other specified applications, which consists the serious inhibitory immune reactions in the body. SSRIs are among these drugs. Therefore, the goal of the current research was evaluating the effectiveness of one of the SSRI Drugs called fluvoxamine on the cytokine level of COVID-19 patients.
Methods: The sample of current research included 80 patients with COVID-19 hospitalized in ICU in Massih Daneshvari Hospital. They entered to the research by accessible method of sampling and then divided in to two groups, randomly. One of the groups underwent the treatment by fluvoxamine, as the experimental group and the other group did not receive fluvoxamine, as the control group. The IL-6 and CRP level were measured both before the onset of fluvoxamine consumption and when discharging from the hospital in all members of the sample group byR&D, Bionik, Delta and Pars Azmoon kits.
Results: The results of the current article showed that the IL-6 increased and CRP level decreased, significantly in experimental group (P.V≤ 0.01). After consuming the fluvoxamine, the IL-6 and CRP levels were more and less, respectively in women compared to men.
Conclusion: Considering the effectiveness of fluvoxamine on important cytokine of IL-6 and CRP in COVID-19 patients, it would be ultimately come true to use this drug in improvement of both psychological and physical conditions, simultaneously and leave the COVID-19 pandemic behind, with less pathology.